QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.050468v1 306/2/646    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Velliquette, R. A. Articles by Ernsberger, P. Search for Related Content PubMed PubMed Citation Articles by Velliquette, R. A. Articles by Ernsberger, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CLONIDINE GLUCOSE Medline Plus Health Information High Blood Pressure Metabolic Syndrome Obesity

ENDOCRINE AND REPRODUCTIVE

The Role of I₁-Imidazoline and ₂-Adrenergic Receptors in the Modulation of Glucose Metabolism in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X

Department of Nutrition, Case Western Reserve University School of Medicine, Cleveland, Ohio

We examined glucose metabolism after I₁-imidazoline (I₁R) and ₂-adrenergic receptor (₂AR) activation in an animal model of metabolic syndrome X. Fasted spontaneously hypertensive obese rats (SHROB) were given the I₁R/₂AR agonists moxonidine and rilmenidine or the ₂AR agonist guanabenz. Because of the dual specificity of moxonidine, its actions were split into adrenergic and nonadrenergic components by using selective antagonists: rauwolscine (₂AR) efaroxan (I₁R/₂AR), or 2-endo-amino-3-exo-isopropylbicyclo[2.2.1.]heptane (AGN 192403) (I₁R). Hyperglycemia induced by moxonidine, rilmenidine, and guanabenz resulted from inhibition of insulin secretion. Similar responses were observed after oral dosing and in lean littermates. Glucagon was reduced by the I₁R agonists (moxonidine, 32 ± 5%; rilmenidine, 24 ± 7%) but elevated by guanabenz (71 ± 32%). The hyperglycemic and hypoinsulinemic responses to moxonidine were blocked by rauwolscine. In contrast, rauwolscine potentiated the reduction in glucagon (39 ± 6%). AGN 193402 blocked the glucagon response without affecting hyperglycemia and hypoinsulinemia. Efaroxan blocked all responses to moxonidine. When SHROB rats were treated with moxonidine 15 min before an oral glucose tolerance test, the glucose area under the curve (AUC) was increased. Antagonizing the ₂AR component of moxonidine's action with rauwolscine improved glucose AUC 3-fold and facilitated the insulin secretory response and reduced glucagon secretion. Testing fasting glucose and insulin during 3 weeks of oral moxonidine revealed early hyperglycemia that later faded, and a progressive drop in fasting insulin. The acute hyperglycemia and hypoinsulinemia elicited by moxonidine and rilmenidine was mediated by ₂AR, whereas I₁R may reduce glucagon and increase insulin, particularly after a glucose load.

Address correspondence to: Dr. Paul Ernsberger, Department of Nutrition, Case Western Reserve University School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106-4906. E-mail: pre{at}po.cwru.edu

This article has been cited by other articles:

				A. Bitto, D. Altavilla, A. Bonaiuto, F. Polito, L. Minutoli, V. Di Stefano, D. Giuliani, S. Guarini, V. Arcoraci, and F. Squadrito Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome J. Endocrinol., March 1, 2009; 200(3): 367 - 376. [Abstract] [Full Text] [PDF]

				Z. Sun and P. Ernsberger Marked Insulin Resistance in Obese Spontaneously Hypertensive Rat Adipocytes Is Ameliorated by in Vivo but Not in Vitro Treatment with Moxonidine J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 845 - 852. [Abstract] [Full Text] [PDF]

				J. K. Saha, J. Xia, J. M. Grondin, S. K. Engle, and J. A. Jakubowski Acute Hyperglycemia Induced by Ketamine/Xylazine Anesthesia in Rats: Mechanisms and Implications for Preclinical Models Experimental Biology and Medicine, November 1, 2005; 230(10): 777 - 784. [Abstract] [Full Text] [PDF]

				R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 422 - 430. [Abstract] [Full Text] [PDF]